PA-21-259: PHS 2021-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2021.
National Institutes of Health offered grants to small businesses. Applications closed on April 5, 2022.
From the official notice on Grants.gov, last changed July 8, 2021. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR43 / R44 / R41
- Clinical trialsNot allowed
- Funded byNIAID, NHLBI, NIGMS
- Median yearly award$624,122
- Typical project length2 years
- R43, Small Business Innovation Research (SBIR) Phase I. A small business tests the feasibility of a technology or product. Other open R43 notices.
- R44, Small Business Innovation Research (SBIR) Phase II. Full research and development of an SBIR project after Phase I (or both phases at once, called Fast Track). Other open R44 notices.
- R41, Small Business Technology Transfer (STTR) Phase I. A small business and a research institution test the feasibility of a technology together. Other open R41 notices.
Projects funded under PA-21-259 were run by National Institute of Allergy and Infectious Diseases (NIAID, 109 projects), National Heart Lung and Blood Institute (NHLBI, 94 projects), National Institute of General Medical Sciences (NIGMS, 78 projects) and National Cancer Institute (NCI, 67 projects), and 28 more. Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read PA-21-259 in the NIH Guide.
Other notices with this title
Key dates
| Posted | July 8, 2021 |
|---|---|
| Deadline | April 5, 2022 |
| Archived by Grants.gov | May 11, 2022 |
Who can apply
This opportunity was open to small businesses.
- Small businesses
Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
Is this a realistic fit?
- Most of the money in the 39 programs behind this notice (70% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
This Funding Opportunity Announcement (FOA), issued by the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA), invites eligible United States small businesses to submit Small Business Innovation Research (SBIR) grant applications. United States small businesses that have the research capabilities and technological expertise to contribute to the R and D mission(s) of the NIH, CDC, and FDA awarding components identified in this FOA are encouraged to submit SBIR grant applications in response to identified topics (see PHS 2021-2 SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, and FDA. This Parent Funding Opportunity Announcement does not accept clinical trials.
Funded under PA-21-259 so far
NIH funded 673 projects under PA-21-259 in fiscal 2022 to 2026, at 562 institutions. The median yearly award was $624,122.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Wearable Sensor and Digital Technologies for Quantitative Assessment and Remote Monitoring of Symptoms in Myasthenia Gravis | Biosensics, LLC | 2026 | $973,917 |
| Development of a stem-cell derived thymic cell therapy to treat patients with athymia | Thymmune Therapeutics, Inc | 2026 | $1.0 million |
| Development of Novel sgp130-Fc Bioconjugates for TBI | Gryphon Bio, Inc. | 2026 | $1.2 million |
| Preclinical Evaluation of a Novel Immunomodulatory Vaccine for Preventing and Treating HSV Infections | Rational Vaccines, Inc. | 2026 | $999,160 |
| First-in-class TREM-1 inhibitors for neovascular retinal diseases | Signablok, Inc. | 2026 | $830,491 |
| A Novel Bispecific Antibody for the Treatment of Idiopathic Pulmonary Fibrosis | Virtici, LLC | 2026 | $903,600 |
| Development of a mechanistically novel synergistic adjuvant to partner with polymyxin antibiotics | Prokaryotics, Inc. | 2026 | $977,454 |
| Carbon Nanotube Enabled Delivery of mRNA for an HIV Vaccine Candidate | Luna Labs USA, LLC | 2026 | $870,685 |
Who has won Allergy and Infectious Diseases Research grants before
From fiscal 2021 to 2025, Allergy and Infectious Diseases Research (93.855) awarded $22 billion across 13,282 grant awards, an average of $1.6 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Fred Hutchinson Cancer Center | Washington | 85 | $938 million |
| Duke University | North Carolina | 230 | $781 million |
| University of California, Los Angeles | California | 138 | $745 million |
| The Johns Hopkins University | Maryland | 321 | $668 million |
| Emory University | Georgia | 282 | $650 million |
Who has won Aging Research grants before
From fiscal 2021 to 2025, Aging Research (93.866) awarded $19 billion across 11,026 grant awards, an average of $1.7 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Regents of the University of California, San Francisco | California | 337 | $575 million |
| The Trustees of Columbia University in the City of New York | New York | 242 | $574 million |
| University of Southern California | California | 203 | $572 million |
| The Washington University | Missouri | 210 | $556 million |
| Regents of the University of Michigan | Michigan | 232 | $538 million |
Who has won Cardiovascular Diseases Research grants before
From fiscal 2021 to 2025, Cardiovascular Diseases Research (93.837) awarded $15 billion across 11,798 grant awards, an average of $1.2 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Trustees of the University of Pennsylvania | Pennsylvania | 313 | $380 million |
| Brigham & Womens Hospital Inc | Massachusetts | 274 | $374 million |
| Regents of the University of Michigan | Michigan | 277 | $355 million |
| The Trustees of Columbia University in the City of New York | New York | 207 | $335 million |
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 295 | $320 million |
Other programs behind this notice
- Biomedical Research and Research Training
- Diabetes, Digestive, and Kidney Diseases Extramural Research
- Extramural Research Programs in the Neurosciences and Neurological Disorders
- Mental Health Research Grants
- Drug Use and Addiction Research Programs
- Child Health and Human Development Extramural Research
- Cancer Treatment Research
- Cancer Biology Research
- Cancer Cause and Prevention Research
- Vision Research
- National Center for Advancing Translational Sciences
- Cancer Detection and Diagnosis Research
- Arthritis, Musculoskeletal and Skin Diseases Research
- Alcohol Research Programs
- Human Genome Research
- Injury Prevention and Control Research and State and Community Based Programs
- Environmental Health
- Research Related to Deafness and Communication Disorders
- Minority Health and Health Disparities Research
- Oral Diseases and Disorders Research
- Discovery and Applied Research for Technological Innovations to Improve Human Health
- Research Infrastructure Programs
- Food and Drug Administration Research
- Cancer Control
- Nursing Research
- Occupational Safety and Health Program
- Research and Training in Complementary and Integrative Health
- Medical Library Assistance
- Strengthening Public Health through Surveillance, Epidemiologic Research, Disease Detection and Prevention
- Prevention of Disease, Disability, and Death by Infectious Diseases
- Environmental Public Health and Emergency Response
- Birth Defects and Developmental Disabilities - Prevention and Surveillance
- Prevention of Disease, Disability, and Death through Immunization and Control of Respiratory and Related Diseases
- Chronic Diseases: Research, Control, and Prevention
- Lung Diseases Research
- Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is PA-21-259 still open?
No. It closed on April 5, 2022.
Who can apply for PHS 2021-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from small businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for PHS 2021-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)?
Closed April 5, 2022. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has been funded under PA-21-259?
NIH RePORTER lists 673 projects funded under PA-21-259 in fiscal 2022 to 2026, at 562 institutions. The most were at Epicypher, Inc., Physical Sciences, Inc, Celdara Medical, LLC.
Who has won Chronic Diseases: Research, Control, and Prevention grants before?
The largest recipients over five fiscal years were New York University, American College of Rheumatology, Inc, Lupus Foundation of America Inc. The program made 88 awards worth $57.3 million in that time.
Similar open grants
- Small Business Transition Grant for New Entrepreneurs (Parent R43/R44 Clinical Trial Optional)
- Small Business Transition Grant for New Entrepreneurs (Parent R41/R42 Clinical Trial Optional)
- NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)
- Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)
- Successor-in-Interest (Type 6 Parent Clinical Trial Optional)
- Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)